SPNE - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to SeaSpine's 2018 Second Quarter Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, July 30, 2018. I would now like to turn the conference call over to Carrie Mendivil, Investor Relations. Please go ahead.

Carrie Mendivil

Thank you for participating in today’s call.

is Valentine; SeaSpine Bostjancic. CFO, from me CEO, and Keith John Joining today, results XXXX. June financial released the Earlier full ended for SeaSpine second quarter XX,

plan, this operations our business within expectations forward-looking and federal will objectives call, strategy, laws meaning for our future securities may financial intend to of the our could, are forward-looking fact results of statements historical believe, During expressions. and statements regard in future similar as plans, Such conference and and condition. include statements than would, such All we will, statements the other make words statements.

cautioned XXXX. place reflect statements, our are of and reliance and which on based on as current information You forward-looking not to belief speak projections XX, are July only only undue today,

uncertainties the are Commission, forward-looking periodic call please releases www.seaspine.com, will and description Valentine. cause results filings Securities at risks now could www.sec.gov. Keith with actual I Keith? our news Exchange our a material the statements, by those which between of stated implied the over available website, and and turn on and that corporate see to the or differences For and

Keith Valentine

Thank afternoon, joining you and all you, us. for thank Good Carrie.

see strong excited second our to are XXXX continue with to We in revenue build the in results momentum quarter.

since QX U.S. rates the education growth medical the that growth highest and and recently increasingly to exclusive experience commitment The posted network market launched Our distributor By in overall we deeper and customer increasing training. marks topline more our continues organization and have engaged spinoff. that growth be to X.X% growth from we reported products and from portfolios. penetration by driven a in X.X% revenue both and a

and a taker in the With product raising be we million of launches to are year second topline expect recent are Accordingly, market revenue a to solid for expectations and we well-positioned and million market the our we of rate our have now in proud and share XXXX. say in momentum to we are to bottom now are $XXX expectations our the growth to continue end We the range accelerate full upcoming be spine. for half of this to that XXXX. share taker revenue $XXX

ahead, solutions focused surgeon solutions value and combine implant developing systems innovative look strategic procedural industry-leading clinical we hospital together improved on our we the centric As will remain to and patient. that vision with surgeon, orthobiologics that cost-effective drive deliver spinal

vision remainder and and are through We to the XXXX look continued this of steadfast executing progress in forward beyond.

increased versus very revenue and was million year Turning to ago the performance, XX.X% increasing X.X% period. million. with slightly which orthobiologics to U.S. last up initial $XX.X stocking spinal U.S. some $XX.X quarter down was our million to $XX total orders million to of revenue second U.S. revenue increasing large International X% compared $X.X included quarter second X.X% implant implants XXXX to spinal year. flat the to $XX.X million

from OsteoStrand families. impact by in in distributors fibers-based recovery our U.S. implants recently revenue quarter of our in on drive by product in DBM with In particular third driven partners the commercial almost and full increasing XX% and by Resorbable launch and together and a solutions. transition the for the NanoMetalene strong surgeons our to the to launch performance was OsteoBallast to a Mesh overwhelmingly expecting We're of OsteoStrand to the quarter. cost-effective have We and end orthobiologics both positive franchise products international provide recently to hospitals been during year-to-date a success continues new year-to-date. the fully quarter expect our XX% XXXX more Orthobiologics be product products increasingly orthobiologics critical half distributor DBM launched procedural in in basis. surgeons the Asia-Pacific Our than XXXX to products and seeking as converting by surface growth are added OsteoStrand more region. second up growth OsteoBallast platform a the was for proprietary payers continues a new second of our and international DBM Feedback led spinal Plus second of the X% and portfolio. the the technology factor the these These

U.S. capacity our additional revenue products California growth expect to long-term manufacturing Irvine XXXX as half facility. with gross We portfolio increased in these margin drive orthobiologics of utilization accelerating at in second the expansion our we

the launched portfolio Mariner we compared since U.S. products for to have devices Turning our and in such than spin and in to XX% bear revenue as ramp legacy systems. fruit. investments more to new product declines interbody outpace to U.S. of quarter of distributor Revenue spinal of implant implant continue have comprise continues we Shoreline made NanoMetalene XXXX. the spinal the second in network from many the implants, revenue The from our XX% enhanced portfolio in quarter spinal systems and the our the our

network. surgeons In of addition, our innovative competitive spinal and in increasingly generated have implants increasingly engaged turn to is by revenue spinal SeaSpine's exclusive a revenue distributors and driving been being These and distributor more in instrumental U.S. a portion larger implants growth. in reducing portfolio new

have from to pipeline many more results we've we'll with exit whom the with with new our partners the high long favorable of recently our our for increasing but XXXX single-digit orthobiologics by our and full distributors U.S. Not of revenue instrument disc and an relationship. We and intuitive double-digit of to distributors our coupled with REGATTA completed us We The spinal implants We and Since decompression distributor penetration distributors posterior leverages embraced on market call the innovative that low we future that our system. implant expectation REGATTA to technology. OsteoStrand quarter. gives have confidence continue our launched and collaboration remain with of compatible XXX(k) And onboarded, commitment combination the launch. lateral the our to lateral we our growth SeaSpine transition our products proprietary in have some system the also and have and line including continued instrumentation implant so in preparation a efficient clearance comprehensive reengaged. the this launch instrumentation fourth system navigation in track retractor be in of May, system effective commercial energy NanoMetalene the complete product received contributions FDA the tenure the just launched the we encouraged for which with

becomes more especially procedures. system surgery programs training increasingly using surgeons their in computer-assisted As for are navigation ubiquitous,

newly to year instrumentation one of this give very decompression navigation instrument As a completed evaluating of reach more the and number result, hospitals systems and interbody successful to most into line Newport instrumentation system we instrumentation extend Fixation used to designed By PLIF posterior expect expand disc positive its sets support SeaSpine The sets our to and third-party the we to to that XXX(k) surgical instruments healthcare have increase sets will Malibu currently us and MIS OR allows have and our of were preparation use launch lordotic surgeries the we expandable TLIF that love cervical that received received of surgeons A we end interbody we the These designed see will ability of device. frequently clearance XX systems new with system. and us of to plan for systems the feedback. the opportunity. orange us. Skipjack that the navigation setting. previously the launch our additional Ventura that Posterior the system extensions visibility of posterior we that the access Mariner and compatible the available NanoMetalene better implant mention, in support all our to Not support are instrumentation

existing our development systems and centric rewarding Our spinal meaningful success our to meet orthobiologics their success our in of organization. the entire this firmly new surgeons our of usage products believe number is implant attracting of approach to product procedurally-based needs surgeons patients. belief validates users surgeon the that and and SeaSpine offerings a and that We surgeon increasing incredibly

value positioning with the providing of SeaSpine on education experience both investment our among company focus as and customer in spine coupled and clinical is innovation Our distributors. world-class further and surgeons medical training and choice increasing

to to we commercial outpace well John are significantly and U.S. expand growth financials John? to outlook share market. our I'll detail to XXXX provide in that financial the our I our more call supported will we the product continue market of launches as We then meaningful spine continue wrap over now confident will on the will take portfolio with up. turn and

John Bostjancic

Keith, Thanks everyone. afternoon good and

$XX million, second launched and which franchise spinal orthobiologics of X.X% DBM to quarter led Keith once revenue total $XX.X products. prior was the revenue led increase million and XXXX and revenue million decreased implant revenue $XX.X by million. slightly our XX.X% of X% increased year. increased revenue. our As implants products comprise to compared in million growth recently XX% was revenue particular growth X.X% by to while launched from $X.X international U.S. than to to U.S. recently for spinal $XX.X earlier, U.S. U.S. more again increased was now the noted in

was was points which of U.S. were the for target The remainder and gross of price from to quarter, expectations to compared quarter the growth same period continue increase quarter prior legacy plan greater third lower new These by high offset half the increased managers the expansion consideration reorganization to in improved we expenses support that compensation Gross expense Operating of second the of Despite declines basis stock-based are driven to acquisition. and remain and to spinal for training growth realistic hiring for successful sales fair in to second for of million, a contingent setting second general XX% we expenses a expect of of decrease strong to NLT liabilities quarter decline with the were and by second to seasonality expenses the continuing $XXX,XXX year. X.X% growth the $XX.X were net sales with spinal million to million revenue $X.X Selling, single-digit period XXXX slight revenue particularly higher approximately the same continuing the increase increase systems. prior associated of the revenue growth. percentage the in growth most increased our the value increases our compensation as year-over-year quarter the compensation. We same the non-cash products the primarily and period usage XXXX these and those with in for launch million of second the for compared in of and XX products. R&D million to really and the decreased by of related of $XX driven in a the by margin lower to margins due newer or $X.X year. of XXXX related in to medical implants to $XXX,XXX associated education partially administrative XXXX. XXXX implant for to compared stock-based related a XXXX. to of to for commissions approximately launch in higher benefit XX.X% The total outpace XXXX second of the product driven primarily quarter $XX.X

of $X.X both for a percentage net quarter expect more and in marketing loss XXXX to XXXX second to XXXX. the second as revenue. loss total a percentage continue sales compared we to and to was XXXX, in we million product in compared absolute Net revenue management quarter to million decline and as dollars education SG&A for of substantially While of medical of of expect the training expense $X a invest

continue We $X XX, revenue credit equivalents XXXX manage facility. to at our and $XX.X totaled growth. carefully June under million on prioritize cash and borrowed to Cash million our cash spin and we investments

sales million redeploy that not sustained to marketing was a quarter second Our $X.X to plan In ATM the driving which sell to so million growth. are net on remain any in savings We of cash-based percentage we under R&D critical burn and of initiatives again XXXX, our focused program. of the the XXXX towards excludes expenses those revenue second continue as $XX reducing revenue outflows financing cash G&A do XXXX. and inflows quarter stock and

and liquidity even expand the years potential three by an at borrowing our for growth This and These second are quickly of expected acceleration extend hand spinal pleased opportunity capitalized production financial sets our investments more facility, long-term on our continue are revenue the achieve up currently attracting sufficiently that for and growth. to they cash focused support ramp successful the access even our to half These flexibility are our believe be least With additional XXXX. at Fargo Wells in incremental capacity. to ready via so million initiatives a investment of credit orthobiologics anticipated We the revenue to products. include year. new amended deploy the end onboarding new greater additional credit us and accelerating critical the of of and we surgeons driver facility on to additional implants provides distributors cash additional the to $XX to are of and to and activities we

XXXX Turning growth for million over are for to to our we as reflects of outlook narrowing X.X% to our range $XXX earlier million X.X% XXXX which revenue $XXX XXXX Keith financial indicated expected full revenue. year to

down P&L, a gross for we increase gross notwithstanding XXXX. we XX% the the Moving range to remainder expect to recent of to margin within of for XXXX XX% remain margin expansion to cautious

orthobiologics the through launches. obsolete charges inefficiencies increases some in we resulting expect associated learning of and the higher the We new and second excess as of costs the continued recent in short-term year work curve from the product inventory with half in ramp products manufacturing manufacturing

We expect call comments. With to R&D revenue. and gains back expenses Keith closing liabilities any SG&A to non-cash contingent I approximate of to NLT to approximate turn to that fair XX% to non-cash X% of like expense related over or in charges the consideration revenue the value of XX% compensation to stock-based XX% XXXX and excluding changes for

Keith Valentine

Thank you, John.

Our strategy we track we continue are in taking believe spine to share for growth remains to SeaSpine on market. poised reposition the and

and as well terrific grow assembled positive a have to at We capabilities our team to are SeaSpine continue continue here our and momentum. operational positioned we commercial

have growing brought and to value and clinical the market on increasingly products to quality hospital the are by focused we surgeon cost-effective more to and than energized differentiated ever of are we patient innovative the We of delivering the success improve lives.

these of continued distribution expansion of open ahead, updating launches, We future education and for surgeon our to forward training that, you Looking in calls. questions. customers. to investments progress it execution our look on distributor defined we up by initiatives and on be and will product now Operator? With medical will reach

Operator

Our first Piper O’Brien Instructions] Matthew question with comes from [Operator Jaffray.

Your line open. is now

Matthew O’Brien

I should the the modeling this. but on one Just by - by X.X million specifically just X.X be or and of for market that clear the about you’re by more of The raising I’m cetera. to bottom want you the the of aware we that million. conservatism is midpoint just level seasonality end a sure yes in about range range year, you of were than Is anything guidance housekeeping there lowered beat we make et the

Keith Valentine

marketplace we year. look it's decade. Matt it you has felt sometimes third number nature, last with in for the if it when quarter And it disasters a been also a important seasonal years the natural littered was last been challenging bit as in even over this of has been

will third conversation is wrapping the so be year. and can the quarter our intent going to quarter talks out make about of And call a third for fourth how how play our quarter to sure next then was the we the different the have that end at up

Matthew O’Brien

a a total been time that little you you’re just you mean a more since color with coming Can bit that historically think growth position taking share in done to some bit business Keith coming I get and can accounts? mentioned your in SeaSpine from is or customers. between for talk from are accounts position you between hadn’t now share spin. you and the where new well more first you has hardware existing starting share more new where little sense. this I existing of about as is which Makes talk - is the the

Keith Valentine

some for continues of has the have in to even more the struggled quarters few larger in there the really be think players quarters and spine been a couple over past space. that I

we’re take able And advantage those of so share of to some market losses.

from And so new I spine gaining larger we coming players. are say those customers I and new think would customers are

In great able addition, go is to in now. thing another deeper we’re accounts

us now better with fully our distribution trained been and that’s at now product. aboard for think a with exclusive than I have year been greater meaning our selling to more have they are ability

We’re we’re in existing able deeper the to in. that accounts go

Matthew O’Brien

me, a And this as SeaSpine as go, far businesses? couple from as across point just at more distributors talk your the exclusive legacy distributors where at they're coverage can And that you distributors. U.S. adopting far as across have about versus their then

John Bostjancic

it year is strategic similar the get the in made decisions from footprint past. distributor distributors The Matt, why the pretty exactly to we're earlier we was is starting more to those where outsized in exclusive growth but the which

in but additional able in hire existing in strength out in as spread as familiar particularly a great in Southwest opening the The deeper with of interest to Keith good accounts, also are more go seeing as attract find of in growth like into portfolio. Mariner having Northwest. deeper that but they new we’re business. discussion existing and as great we sort said accounts like And folks point flagship they We’re the to go accounts, the Texas portfolio of Shoreline is new the that so kind deeper going to ultimately move products they get and

Matthew O’Brien

Make driving the a that number all compares visibility little know to as you to sets were time John new growth us Can as future? or sets introducing. talking because we sense, you major in of year how that's me. last from factor this about that last you’re the on give one be as far going

John Bostjancic

with the surgeons being success Yes, and picking really making Shoreline our bets. those expanding in little We XX so business. over products year third last and are the new the launched to and distributors sets foundational biggest and Mariner quarter of up

increasing sets example Shoreline about Mariner by numbers of for for and We’re the XX%.

Ventura our line sets We’re another or going extension. for add so to XX

and to surgeons the that focus the because been how it's seen board, able well Mariner has our attract new success of Shoreline and on and be just primary So across really distributors. but we've to starting

there, So the we're plans of increase starting sets NanoMetalene well. but other interbody to as

Operator

comes Zimmerman Our BTIG. next Ryan with question from

Your line is now open.

Ryan Zimmerman

on questions Could this traditionally for asking. was something orthobiologics not it's a the So just - you Matt the quarter, was growth hardware just that to color the on provide strong want follow-up really carried couple little more a company.

And specifically those on of year? on osteobiologics drove and about thinking And OsteoStrand how gains your the OsteoBallast, some and we so category. with those pull-through just color then product more half products of back the be your the thoughts on should in what the kind

Keith Valentine

as and in growth but we’re Shoreline in Mariner smaller the line we a pull-through that. from revenue The orthobiologics from seeing carry shift to out Ventura the a we’re hardware. growth, its again extension to Yes, orthobiologics led the that coming good rolled percentage continuing of competitive see distributors

direction tend that right continuing both exclusive to the from board that's we So portfolios one. still the because the bring of in day the on newer more more and trend distributors carry

said the we’re getting I the where mass of that orthobiologics critical as earlier growth on starting implants Most revenue well. as but move As have that needle. that's side, pronounced pull-through a also to revenue

John Bostjancic

I keep the think in seven years Ryan these and that orthobiologic or group product the that also for specifically that not haven’t are us category just new new a launched orthobiologics in have products mind greater.

in And on all to traction so contract get of continues there and time into to a that on product of kind is just product takes is traction the right. go get it some has getting of hospitals that and because portfolio to orthobiologics still new process the getting as

down traditional of are new at encouraged with and pleased portfolio a products to continue DBM really formula strength getting actually the we we’re the really hospitals. the knock on continued pricing So still product because

the think we see to and headed close XXXX. So you’ll year as up pick to start that momentum I

Ryan Zimmerman

may the this international But you I know. later Pac in than have mentioned, you think a don't out you it called that maybe I then next few Asia year sooner months in distributor thoughts onboard coming looking And expect just distributors further out kind we cadence take be your your international what you time? the on of can a want little where to over out business and or international of

Keith Valentine

U.S. philosophies to conversations what robust spinal Europe. if I calls will what to the better and on very it had in biggest has so was the in we is penetration a we you Yes, even do common some we implant have we of need opportunity mentioned in Australia in previous Australia. market do think views

So expansion that was a us. logical for

to XXXX CE As a deeper we’ll go is that is those so will - on to there internationally. we products. South happen have forward approvals cadence additional expand will to into and Europe will move and couple with products more with opportunity. we then that continue do expansion There And and regulatory continue with become we’ll products be markings moving for distributors Europe Thanks a available. new more able America both to our things in forward going

us now that the like to and feel there countries new to getting also are new we product different approvals able product lines traction, So going enable that’s in regulatory as good lines offer get we’re well. to

Operator

with Craig Fitzgerald. from Bijou comes question next Our Cantor

line Your now is open.

Craig Bijou

brought quarter And I I - distributors. the congrats to just I I on start some with want mean the in quarter on again. you will know

one-time any during So that items quarter? you would characterize or the unusual growth the in embedded items

Keith Valentine

go is message you’re what seeing couple No, that exclusive you on kind spinal in we things right. line especially aboard the implant bringing of

step making and quarter is to to in getting focused real hospital reps them our on education those and the second get you're traction see the starting on in are first seeing part getting that you’re of but very more starting engaging territories they’re products, now that line. is them have our speed to are on I distributor what larger And additionally what up as The as opportunity, exclusives think you experienced the you're approvals far to now. product their up speed sure

areas distributor so for the of that and those attention the in time. for areas us And focus greatest greatest we had lift

Craig Bijou

a maybe a picture on Just the question bigger bigger distributors.

old you’re for getting the willing had. kind new you explicit/implicit that may of on cycle them? go launch the and as bringing are you what re-energizing be getting of What commitments your next through that the product invest ones from several guys they Any years on you’re products. to or commitments you from insurances you’re of distributors lot obviously So ones a new some color

Keith Valentine

in a exclusive I investing and hiring part it’s really they that commitments education of think the they we about commit training to and and as this to is when business is the drive their and we Yes, the can to partnership are aboard business bringing number reps well. mean new is process to know of what what the doing I to commitment want think that want what mutual that know both

And so, from we’re earlier I view street getting plan I sit we trying their to obviously commitments a bring is, part down, more guess is two-way and always push of to it them just than explore business later do on more reps right.

I I those reps seen get aboard willing know our in that's that that aboard to to the out time distributors make think groups was we that are lag second those that would all the investing early we best there ones and the in and those we are want are partnerships largely that's driven and success investment. that think quarter getting by the where

Craig Bijou

give orthobiologics longer-term of spinal for wondering that year And can low color single-digit, can double-digit when next And you still first expect that if of or years. couple whatever as then do to breakdown growth level you do you level the see with the if think can you you about you that maybe, growth? growth on a maybe U.S. OUS exit implants the can of high guys that versus you

John Bostjancic

do. we so Yes,

single-digit double-digit low how next portfolio rates. that ensure very we’re growth will this what high our that innovation, will strategic be the steps product we can approaching We’re maintain focused

launch to number will to see OUS to see but maintain growth XX% view that investments penetration that like something then rate, don't also be in XX%, getting later least I but se, XX% XX% OUS a would is generated into as we that that out ability the as come per at get and that them to to the OUS. to it further in in of new I XX% years products be we have as going hope grow like it's more business to significant is a starting XXXX/XXXX. organization. Our well. opportunities these do for approach as of to XX% higher that to I'd continue There

Operator

Our Thalmann. next question Jeff comes Ladenburg with from Cohen

Your line is now open.

Jeff Cohen

expect of could what clarity provide John got on half the I the may bit year as on hardware of lines. on, innovations margin versus side? you a more back as or margins on fair you’ve product color But you amount going far both that firstly little So the a for any know further biologics

John Bostjancic

new learning continue ramp the to right And strategically for because we on thing orthobiologics legacy a continue long-term risks. we’ve fibers We on the I new good the themes continuing. obsolete curve. which think the that we’re of the past up creates talked launch charges of from of we intentionally cautious and product there's a were us implants ballast are we inventory products and so the sunset in year the No think the risk as about is system production launches middle side to some and because side products same in that the all the know and excess new

that our new product but control launched years we Irvine. homegrown all manufacturing and mentioned site, to a seven that as in the capacity that manufacturing we in development and particularly manufacturing it's Keith facility products haven’t add up ramp We’re Irvine to so those in great know

and also in ballast site by going driven products So shift a as forward. year will produce by also there be to but change the to really a shift increasing terms be as for expectations it's no newer ramp the the you for attention products the Irvine portfolio, we excited able cautious making manufacture gross and learning them that margins we the focus going new which think are through on fibers the something this we growth they're or products that legacy up when to be and knowing new production. And of challenge in like But oriented curve longer-term our to is even new want the we orthobiologics to but the expansion continue volume the just a product that side. dramatic

Jeff Cohen

or side And towards seeing Are could and about talk more you your the there. getting products the users. great? some pulling navigation is or least And robotics hardware provide both you a further little sets as cervical and about seeing Could Mariner you that and pulling for more far Thanks. out color, at robotics are you any from navigation. talked as would be you thoracic that colors the or

John Bostjancic

the requiring right. what number care they there's so big surgeons settings have big of is pulling either the think at that I least in hospitals compatible question think practices degenerative that some with degenerative own larger facility. don’t already it's their And or are Yes, of first I requiring a - or on

ability So compatibility was sets that's what that leading navigation with with we have were do we referring our to the the in instrument systems. call

continue So to specific might want process we or a navigation be a navigation to them into system have be having keep that areas different as compatible proprietary that we with. and system we with will faced we’ll expanding to it be do a continual

of moving of the second part the of question On - saying you’re point on that the Jeff. point deformity the Mariner into was

Jeff Cohen

just also weaknesses further on And any and strengths, other cervical risks. orthoracic clarity general

John Bostjancic

sets go great and as I think want They've the very our out procure will to business. part of they having momentum we had they’ve them what available try Mariner they also been launches. for we’re good and seeing with Shoreline mentioned new are to enable we we’re that both distributors confidence is give that and investments have good as the partnerships

of channels large supported. and one fear distribution points they of not think have whether I with can the and bringing on surgeon a a new they sticky distributors be many are

the in to to obligation feel plan business, sure clear that. want they do advance partnership for who they to we them grow make that those have that we’re committed it's a sets this our to how park of that so distributors And can so and

Operator

question Wainwright. with next from Our Ramakanth Swayampakula comes H.C.

is open. now line Your

Swayampakula Ramakanth

is the questions, couple a at If of have what look year and at view year-over-year can and on last from of of of at had at reported and so year for here. I what this remained witnessed assume different now you situation time set look quite quite like - But growth have than question you how have your had the I you different it have profile distributors what better just I the the first rate far. look the same which future guidance you cannot your rest so similar guidance, a a year understand. different at looks products, far have the is the the SeaSpine that and you you seen is momentum conservative you

the done. one-third of quarter So, is and already

the what what that's or not the rest are rush seeing you is outside .I'm wait and that are be feel see the the within are industry for watch why talking just about in the that let's you year? company making something in and folks you kind the of company bullish only of - So that ourselves to seeing able not

John Bostjancic

really I the quarter. you’re to it, the goes third what off we that and think call kicked when Okay, taking hear back I but was question it direction the first

fall that and think quarter has the decade, a I over seasonal spine. in into couple you back even can challenges out look And seasonal disasters third last quarter other back in look addition you a being natural If it sometimes point has a been also on. challenging it instances and quarter, where

in on We look stance And kind the conservative the how quarter. quarter bullish of third so intent at fourth quarter. our understand we’re that we was be uptick still extremely to fourth in the the get through of the

We will biggest up much to we should a And in will September. year perspective. call going that also that give understand we much just with feel like how distribution progress closing that and from range perspective a from greater we and the in had year coming to up sure fourth thoughtful greater of the quarter clarity third going is uptick what clarity on give be. quarter product and that with certainly on have that the we a post launch NAS make to want What what meaning overlap have we of the the third

Swayampakula Ramakanth

question in certainly on going to right giving you orthobiologics it a seems Then momentum. the be and further direction

So where couple for spending are second half some the how you're a pulls energy second pushes you half, see just portfolio next years yourself but what place for think just this build the would segment only in up? also I of this not to because the that in is and the

Keith Valentine

moving sure have DBM DBM strong franchise. was under making very Yes is franchise this been that that a certainly while - we’ve rare traditional launch very we

product organization accounts of as to been our business gain new launches as much with business wanting distribution right. deeper in as and to these really focus so, our And focus use our And that additional maintain possible. has channel, go an

competitive competitively. products to after after these a We at but much new doing studies well in business instead to we have feel like other idea more done well, go it’s the strand the material that premium are the the have that orthobiologics is go so additional wasn't necessarily biologics to obsolete so good price. the completely opportunity it products so after ability our has So go to

of And so on orthobiologics these and the we that, to hospital and the that contract have with getting does take them on time. pricing to task getting also

sometimes and new be process months, submit a for products but to Sometimes it can it be can pricing. it is weeks

doing quarter those into think us so which and And speak both good as positions momentum for strong well XXXX. we’re fourth we of I really a

your we than much how question in be hospitals premium second have the space we to price. cost-effective it the will plays more So have at of pricing able have a compete ability is once perspective, greater offer with since orthobiologics to out it those we a feel a and head-to-head half it contracts, I from

Swayampakula Ramakanth

that to, to from that this you which percentage some get last business this have currently tell other be the me share and on us all at The what implant time. developed. you spinal that the also benefiting point? number can question Could as distributor is exclusive maintain market the just need grow there your like to seems closing distributors you're are enjoying increasing at that from relations you And the optimal of you is

John Bostjancic

number hasn’t been. where changed the it’s from dramatically Yes, overall

longer representing spinal we I bring And exclusive. side. carrying half and as on mutual in again to Keith there want this and orthobiologics, more reengage in on number think near of or getting tenure becoming implants the of is distributors the them some a revenues and we’re to push of and each direction And those other. to whitespace at continue close both continue the magic those XX distributors hardware point try to investment our no exclusive add they’re on really it’s said to XX to before,

growth revenue growth. the innovative the they definitely add just results know we cost launch only that near magic continue no to of the we new we that I we the that's that kind past more newer exclusivity, find and the pleased exclusive get growth but looking now sustaining but distributors prior distributors of revenue that strategic there's that term from. over a longer driving we’re think ourselves we’re sustainability for number to foundation distribution legacy good work And term have of the three through we more dedication forward. not revenue, away products for And changes about and was want made revenue with of we where headwinds it to those service of the growth mass the years in years that going but is us We’re moving because critical revenue to net moved

Operator

At questions. over this call time, for back turn the I’d I’m showing no remarks. to like further closing

Keith Valentine

today evening. a us great for have you Thank joining and everyone

Operator

conclude your the for participation and This you Ladies program. in thank conference. gentlemen, today’s does

day. You have may great now disconnect. Everyone a

SeaSpine (SPNE) 30 Jul 182018 Q2 Earnings call transcript